Prognostic evaluation of electrocochleography in idiopathic sudden sensorineural hearing loss.
CONCLUSIONS
Abnormal action potential (AP) recovery from adaptation was manifested as increased recovery (iR) or decreased recovery (dR) relative to the normal recovery range. dR was not analyzed statistically due to the very small number of cases. iR is considered an unfavorable prognostic indicator, whereas a normal AP recovery (nR), enhanced SP/AP ratio (≥0.35), and lower AP threshold are favorable prognostic indicators for idiopathic sudden sensorineural hearing loss (iSSNHL).


OBJECTIVE
This study aimed to determine the prognostic efficacy of AP recovery examinations associated with other electrocochleography (ECochG) findings in iSSNHL.


METHODS
ECochG was performed transtympanically in 58 iSSNHL ears. AP recovery was measured by a paired-click stimulation paradigm, and hearing outcome was classified into three groups. Additionally, the relationships of other confounding prognostic factors to hearing outcomes were assessed.


RESULTS
iR was significantly more common in the no-recovery group, while nR and an enhanced SP/AP ratio were significantly more common in the cure and improvement groups. The AP threshold was significantly lower in the cure group than in the other two groups. The other confounding prognostic factors generally showed similar trends to those reported previously.
Department of Otorhinolaryngology, Hadano Red Cross Hospital, Hadano-Si, Kanagawa-Ken, Japan. tohashi@vc-net.ne.jp
Toru
T
Ohashi
Horohito
H
Nishino
Yoko
Y
Arai
Yositane
Y
Nishimoto
Izumi
I
Koizuka
D000200:Action Potentials / Q000502:physiology*; D000255:Adenosine Triphosphate / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000627:therapeutic use; D000704:Analysis of Variance; D001300:Audiometry, Evoked Response; D001309:Auditory Threshold / Q000502:physiology; D005938:Glucocorticoids / Q000627:therapeutic use; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy / Q000503:physiopathology*; D003639:Hearing Loss, Sudden / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D008875:Middle Aged; D011239:Prednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D011379:Prognosis; D020127:Recovery of Function / Q000502:physiology; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use; D014717:Vertigo / Q000150:complications; D055815:Young Adult
D005938:Glucocorticoids; D014665:Vasodilator Agents; D000255:Adenosine Triphosphate; D011239:Prednisolone; D000527:Alprostadil; C021322:prednisolone hemisuccinate